scispace - formally typeset
E

Elana Godebu

Researcher at University of California, San Diego

Publications -  14
Citations -  355

Elana Godebu is an academic researcher from University of California, San Diego. The author has contributed to research in topics: FOXP3 & IL-2 receptor. The author has an hindex of 7, co-authored 14 publications receiving 323 citations. Previous affiliations of Elana Godebu include UC San Diego Health System.

Papers
More filters
Journal ArticleDOI

Adaptive Islet-Specific Regulatory CD4 T Cells Control Autoimmune Diabetes and Mediate the Disappearance of Pathogenic Th1 Cells In Vivo

TL;DR: The results suggest that adaptive regulatory CD4 cells may control diabetes in part by impairing the survival of islet-specific Th1 cells, and thereby inhibiting the localization and response of autoaggressive T cells in the pancreatic islets.
Journal ArticleDOI

Polyclonal Adaptive Regulatory CD4 Cells That Can Reverse Type I Diabetes Become Oligoclonal Long-Term Protective Memory Cells

TL;DR: Adaptive TR cells, which can be readily generated from normal CD4 populations and become focused by Ag with induction of memory, may provide a treatment and a vaccine for the long-term cure of diabetes making them attractive as immunotherapeutic agents.
Journal ArticleDOI

The effect of restrictive bariatric surgery on urolithiasis.

TL;DR: This study demonstrates a very low incidence of kidney stones after restrictive bariatric procedures, although larger sample sizes, longer follow-up times, and controlled prospective studies are necessary to validate this finding.
Journal ArticleDOI

Does Listening to Music During Office-Based Flexible Cystoscopy Decrease Anxiety in Patients: A Prospective Randomized Trial.

TL;DR: To validate the effect of listening to music on perceived anxiety and pain during office-based flexible cystoscopy using the State-Trait Anxiety Inventory (STAI) and the Visual Analog Scale (VAS), in a well-matched North American veteran patient population in a prospective, randomized fashion.
Journal ArticleDOI

PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche

TL;DR: PCSD1 is a new primary prostate cancer bone metastasis-derived xenograft model to study bone metastatic disease and for pre-clinical drug development of novel therapies for inhibiting therapy resistant prostate cancer growth in the bone-niche.